Successful treatment of aggressive AA amyloidosis with tocilizumab in a patient with polymyalgia rheumatica

Atas N., Çalışkan A. R., Akatlı A.

Modern Rheumatology Case Reports, cilt.9, sa.1, ss.214-217, 2025 (ESCI, Scopus) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 9 Sayı: 1
  • Basım Tarihi: 2025
  • Doi Numarası: 10.1093/mrcr/rxae050
  • Dergi Adı: Modern Rheumatology Case Reports
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus
  • Sayfa Sayıları: ss.214-217
  • Anahtar Kelimeler: AA amyloidosis, IL-6, Polymyalgia rheumatica, proteinuria, tocilizumab
  • İnönü Üniversitesi Adresli: Evet

Özet

Polymyalgia rheumatic (PMR) associated amyloidosis is an extremely rare condition that can be rapidly progressive with high morbidity and mortality and management is challenging. Tocilizumab is a monoclonal anti–IL-6 receptor antibody, which is in the therapeutic arsenal of PMR. The efficiency of tocilizumab in improvement of PMR activity score and decreasing steroid dose is well-established, while efficiency in PMR–associated amyloidosis has not been published. Herein, we reported a PMR patient with amyloid A amyloidosis who was treated effectively with tocilizumab.